Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

BACKGROUND: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchler, Tomas, Pavlik, Tomas, Melichar, Bohuslav, Bortlicek, Zbynek, Usiakova, Zuzana, Dusek, Ladislav, Kiss, Igor, Kohoutek, Milan, Benesova, Vera, Vyzula, Rostislav, Abrahamova, Jitka, Obermannova, Radka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018966/
https://www.ncbi.nlm.nih.gov/pubmed/24884897
http://dx.doi.org/10.1186/1471-2407-14-323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018966/
https://www.ncbi.nlm.nih.gov/pubmed/24884897
http://dx.doi.org/10.1186/1471-2407-14-323

Ejemplares similares